Search - Université de Rennes Access content directly

Filter your results

13 Results
Structure: Internal structure identifier : 221301
Image document

Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial

Vincent Ribrag , Serge Koscielny , Jacques Bosq , Thibaut Leguay , Olivier Casasnovas et al.
The Lancet, 2016, 387 (10036), pp.2402 - 2411. ⟨10.1016/S0140-6736(15)01317-3⟩
Journal articles inserm-01419476v1
Image document

Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study.

Mira Tout , Olivier Casasnovas , Michel Meignan , Thierry Lamy , Franck Morschhauser et al.
Blood, 2017, 129 (19), pp.2616-2623. ⟨10.1182/blood-2016-10-744292⟩
Journal articles hal-01547802v1

Nivolumab Is Effective and Reasonably Safe in Relapsed or Refractory Hodgkin's Lymphoma after Allogeneic Hematopoietic Cell Transplantation: A Study from the Lysa and SFGM-TC

Loic Ysebaert , Roch Houot , Ibrahim Yakoub-Agha , Franck Morschhauser , Charles Herbaux et al.
Blood, 2015, 126 (23), pp.3979-3979
Journal articles hal-01290424v1

Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study

Guillaume Cartron , Sophie de Guibert , Marie-Sarah Dilhuydy , Franck Morschhauser , Veronique Leblond et al.
Blood, 2014, 124 (14), pp.2196--2202. ⟨10.1182/blood-2014-07-586610⟩
Journal articles hal-01147035v1

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

Sophie Langner-Lemercier , Caroline Houillier , Carole Soussain , Hervé Ghesquières , Olivier Chinot et al.
Neuro-Oncology, 2016, 18 (9), pp.1297-1303. ⟨10.1093/neuonc/now033⟩
Journal articles hal-01290413v1

A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma

Bertrand Coiffier , Catherine Thieblemont , Sophie de Guibert , Jehan Dupuis , Vincent Ribrag et al.
British Journal of Haematology, 2016, 173 (5), pp.722-730. ⟨10.1111/bjh.13992⟩
Journal articles hal-01295660v1

A dose-escalation study of SAR3419, an anti-CD19 antibody maytansinoid conjugate, administered by intravenous infusion once weekly in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Vincent Ribrag , Jehan Dupuis , Herve Tilly , Franck Morschhauser , Fabrice Laine et al.
Clinical Cancer Research, 2014, 20 (1), pp.213--220. ⟨10.1158/1078-0432.CCR-13-0580⟩
Journal articles hal-01068681v1

Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA

Roch Houot , Carole Soussain , Hervé Tilly , Corinne Haioun , Catherine Thieblemont et al.
Annals of Oncology, 2016, 27 (7), pp.1349-50. ⟨10.1093/annonc/mdw138⟩
Journal articles hal-01295653v1

Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions

Ciara L. Freeman , Franck Morschhauser , Laurie Sehn , Mark Dixon , Richard Houghton et al.
Blood, 2015, 126 (24), pp.2646--2649. ⟨10.1182/blood-2015-09-670802⟩
Journal articles hal-01275480v1

Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.

Emilie Reboursiere , Fabien Le Bras , Charles Herbaux , Emmanuel Gyan , Aline Clavert et al.
Oncotarget, 2016, 7 (51), pp.85573-85583. ⟨10.18632/oncotarget.10764⟩
Journal articles hal-01475957v1

Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program

Aurore Perrot , Hélène Monjanel , Reda Bouabdallah , Philippe Quittet , Clémentine Sarkozy et al.
Journal articles hal-01259439v1
Image document

Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma.

Emmanuel Bachy , Roch Houot , Franck Morschhauser , Anne Sonet , Pauline Brice et al.
Haematologica, 2013, 98 (7), pp.1107-14. ⟨10.3324/haematol.2012.082412⟩
Journal articles hal-00933219v1

Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial

Reinhard Marks , Lorenz Trümper , Tsvetan Biyukov , Meera Patturajan , Marie-Laure Casadebaig Bravo et al.
Lancet Oncology, 2016, 17 (3), pp.319-331. ⟨10.1016/S1470-2045(15)00559-8⟩
Journal articles hal-01274886v1